Stock Watch: One Acquisition Does Not Make A Biotech M&A Boom
Pfizer’s Pandemic Success Finally Prompts A Transaction
Another blow-out quarter from Pfizer provided the impetus for an acquisition. But the history of recent commercial-stage biotech transactions and the risky nature of all early-stage companies suggest that the floodgates will not burst open.
You may also be interested in...
Stock Watch: Spanners In The Works For Q4 Results
While the implications of the US Inflation Reduction Act are the focus of the sector’s concern this year, another regulatory development will impact earnings sooner.
Pfizer On Paxlovid: "There's Still A Long Way To Go"
Access to the COVID-19 treatment is broadening, but Pfizer says there is still work to do when it comes to getting the antiviral to patients quickly.
Stock Watch: Pfizer Caught Between The Pandemic And The Recovery
The pandemic is bad for Pfizer’s hospital products and traditional vaccine sales – but recovery is less good for Comirnaty and Paxlovid. Were investors right to be underwhelmed by Pfizer’s 2022 projections?